Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy

References

• McDonald JS. Adjuvant therapy of colorectal cancer. CA Cancer 1 Gun. 49, 202–219 (1999).
   Google Scholar
• •Overview of current adjuvant treatment options for colorectal cancer.
   Google Scholar
• O'Connell MJ, Schaid DJ, Ganju V et al. Current status of adjuvant therapy of colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 70(Suppl.), 1732–1739 (1992).
   Google Scholar
• McLeod HL, Murray GI. Tumor markers of prognosis in colorectal cancer. BE Cancer79, 191–203 (1999).
   Google Scholar
• •Overview of prognostic markers in colorectal cancer.
   Google Scholar
• American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.j Clin. Oncol 14,2843–2877 (1996).
   PubMedGoogle Scholar
• ••Comphensive analysis with levels ofevidence of prognostic markers in colorectal cancer.
   Google Scholar
• Chapman MA, Hardcastle JD, Armitage NC. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 76,383–387 (1995).
   Google Scholar
• •Prognostic role of ploidy in a prospective study.
   Google Scholar
• Tomoda H, Baba H, Saito T, Wada S. DNA index as a significant predictor of recurrence in colorectal cancer. Dis. Colon Rectum 41, 286–290 (1998).
   PubMedGoogle Scholar
• Takanishi DM, Jr., Hart J, Covarelli P, Chappell R, Michelassi E Ploidy as a prognostic feature in colonic adenocarcinoma. Arch. Surg. 131,587–592 (1996).
   PubMedGoogle Scholar
• Purdie CA, Pins J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. klistopathology36, 121–126 (2000).
   PubMedGoogle Scholar
• Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin. Cancer Res. 5,1793–1804 (1999).
   PubMedGoogle Scholar
• •Prognostic role of ploidy in node-negative colorectal cancer.
   Google Scholar
• Lanza G, Gafa R, Santini A et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 82,49–59 (1998).
   PubMed Web of Science ®Google Scholar
• •Prosepctive study on the prognostic role of ploidy in node-negative colorectal cancer.
   Google Scholar
• Non i D, Merimsky 0, Saw D, Cortes E, Chen E, Chassin J. Tumor ploidy as a risk factor for disease recurrence and short survival in surgically treated Dukes' B2 colon cancer patients. Tumour Biol. 17,75-80 (1996).
   Google Scholar
• •Prognostic role of ploidy in node-negative colorectal cancer.
   Google Scholar
• Salud A, Porcel JM, Raikundalia B, Camplejohn RS, Taub NA. Prognostic significance of DNA ploidy, S-phase fraction and P-glycoprotein statement in colorectal cancer. I Surg. Oncol 72,167–174 (1999).
   Google Scholar
• Cosimelli M, D'Agnano I, Tedesco M etal. The role of multiploidy as unfavorable prognostic variable in colorectal cancer. Anticancer Res. 18,1957–1965 (1998).
   Google Scholar
• Tang R, Ho YS, You YT eta]. Prognostic evaluation of DNA flow cytometric andhistopathologic parameters of colorectal cancer. Cancer 15,1724–1730 (1995).
   Google Scholar
• Zarbo RJ, Nakhleh RE, Brown RD, Kubus JJ, Ma CK, Mackowiak P. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry. Cancer79, 2073–2086 (1997).
   PubMed Web of Science ®Google Scholar
• Cascinu S, Ligi M, Graziano F et al. 5-phase fraction can predict event free survival in patients with T2-3NOMO colorectal carcinoma. Cancer 83,1081–1085 (1998).
   Google Scholar
• •Prognostic role of SPF in node-negative colorectal cancer.
   Google Scholar
• Chen YT, Henk MJ, Carney KJ et al. Prognostic significance of tumor markers in colorectal cancer patients: DNA index, 5-phase fraction, p53 statement and Ki-67 index.j Castmintest. Surg. 1,266-273 (1997).
   Google Scholar
• al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen statement in colorectal cancer. Cancer 71,1954–1959 (1993).
   Google Scholar
• Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival. Cancer 77, 1741–1746 (1996).
   Google Scholar
• Choi HJ, Jung IK, Kim SS, Hong SH. Proliferating cell nuclear antigen statement and its relationship to malignancy potential in invasive colorectal carcinomas. Dis. Colon. Rectum 40,51–59 (1997).
   PubMedGoogle Scholar
• Nakae S, Nakamura T, Shirono J eta]. Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in colorectal cancer. I Surg. Oncol 60,149–153 (1995).
   Google Scholar
• Kovac D, Rubinic M, Krasevic M eta]. Proliferating cell nuclear antigen (PCNA) as a prognostic factor for colorectal cancer. Anticancer Res. 5,2301–2302 (1995).
   Google Scholar
• Guerra A, Borda F, Javier Jimenez F, Martinez-Penuela JM, Larrinaga B. Multivariate analysis of prognostic factors in resected colorectal cancer, a new prognostic index. Eur. j Castroenterol Hepatol 10,51–58 (1998).
   Google Scholar
• Sun XF, Carstensen JM, Stal 0, Zhang H, Nordenskjold B. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int. I Cancer69, 5–8 (1996).
   Google Scholar
• Neoptolemos JP, Oates GD, Newbold KM, Robson AM, McConkey C, Powell J. Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. BE Surg. 82,184–187 (1995).
   PubMedGoogle Scholar
• Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. BE j Cancer 79, 577–581 (1999).
   Google Scholar
• ••
   Google Scholar
• Jansson A, Sun XF. Ki-67 statement in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS105,730–734 (1997).
   PubMed Web of Science ®Google Scholar
• Kyzer S, Gordon PH. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody 1(167. Dis. Colon Rectum 40,322–325 (1997).
   Google Scholar
• Linden MD, el-Naggar AK, Nathanson SD, Jacobson G, Zarbo RJ. Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Mod. Pathol 9, 682–689 (1996).
   Google Scholar
• Hemming AW, Davis NL, Kluftinger A et al Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor and Ki-67. I Surg. Oncol 51,147–152 (1992).
   Google Scholar
• Ofner D, Grothaus A, Riedmann B et al. MIB1 in colorectal carcinomas: its evaluation by three different methods reveals lack of prognostic significance. Anal Cell Pathol 12,61–70 (1996).
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis and tissue factors. Nature Med. 2,167–168 (1996).
   PubMed Web of Science ®Google Scholar
• ••Review on tumor angiogenesis in cancer.
   Google Scholar
• Galindo Gallego M, Fernandez Acenero MJ, Sanz Ortega J, Aljama A. Vascular enumeration as a prognosticator for colorectal carcinoma. Eurj Cancer 36,55–60 (2000).
   PubMedGoogle Scholar
• •Prognostic role of angiogenesis in colorectal cancer; review of previous studies with vascular count.
   Google Scholar
• Giatromanolaki A, Stathopoulos GP, Tsiobanou E et al. Combined role of tumor angiogenesis, bc1-2 and p53 statement in the prognosis of patients with colorectal carcinoma. Cancer86, 1421–1425 (1999).
   PubMedGoogle Scholar
• Vermeulen PB, Van den Eynden GG, Huget P et al. Prospective study of intratumoral microvessel density, p53 statement and survival in colorectal cancer. Br. Cancer79, 316–22 (1999).
   Google Scholar
• Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DR Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann. Sing. 222,695–699 (1995).
   Google Scholar
• •Prognostic role of angiogenesis in node-negative colorectal cancer.
   Google Scholar
• Banner BF, Whitehouse R, Baker SP, SwansonRS. Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am j Clin. Pathol 109,733–737 (1998).
   PubMedGoogle Scholar
• •Prognostic role of angiogenesis in node-negative colorectal cancer.
   Google Scholar
• Takahashi Y, Tucker SL, Kitadai Y et al. Vessel counts and statement of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 132,541–546 (1997).
   PubMed Web of Science ®Google Scholar
• •Prognostic role of angiogenesis in node-negative colorectal cancer.
   Google Scholar
• Maeda K, Nishiguchi Y, Yashiro M et al. Statement of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int. j Mal Med. 5,373-378 (2000).
   Google Scholar
• Cascinu S, Staccioli MP, Gasparini G et al. Statement of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 6, 2803–2807 (2000).
   PubMed Web of Science ®Google Scholar
• •Prognostic role of angiogenesis in node-negative colorectal cancer.
   Google Scholar
• Kong SM, Maeda K, Chung YS. Vascular endothelial growth factor statement correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep. 4,381–384 (1997).
   Google Scholar
• Amaya H, Tanigawa N, Lu C et al. Association of vascular endothelial growth factor statement with tumor angiogenesis, surival and thymidine phosphorylasei platelet-derived endothelial growth factor statement in human colorectal cancer. Cancer Lett. 119,227–235 (1997).
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor statement in colorectal cancer patients. Eur. I Cancer36, 748–753 (2000).
   PubMed Web of Science ®Google Scholar
• •Prognostic role of angiogenesis in colorectal cancer; review of previous studies with VEGF analysis.
   Google Scholar
• Ishigami SI, Arii S, Furutani M et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. BE j Cancer78, 1379–1384 (1998).
   Web of Science ®Google Scholar
• Tokunaga T, Oshika Y, Abe Y et al. Vascular endothelial growth factor (VEGF) mRNA isoform statement pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. Cancer 77,998–1002 (1998).
   Web of Science ®Google Scholar
• Mosaic" T, Matsuoica H, Sugiyama M et al. Matrilysin (IVIMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. BE J. Cancer 84,1317–1321 (2001).
   Google Scholar
• Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Tinto 14,659–666 (2000).
   Google Scholar
• Oberg A, Hoyhtya M, Tavelin B et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases TIMP-2) in colorectal cancer. Anticancer Res. 20,1085–1091 (2000).
   PubMed Web of Science ®Google Scholar
• Sunami E, Tsuno N, Osada T et al. MMP- 1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2, 108–1014 (2000).
   Google Scholar
• Zeng ZS, Cohen AM, Zhang ZF et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin. Cancer Res. 8, 899–906 (1995).
   Google Scholar
• Ring P, Johansson K, Hoyhtya M et al. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer: a predictor of tumour stage. Br. Cancer6, 805–811 (1997).
   Google Scholar
• Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. j Clin. Oncol 12, 3133–3140 (1996).
   Google Scholar
• Murray GI, Duncan ME, O'Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 4,461–462 (1996).
   Google Scholar
• Liabakk NB, Talbot I, Smith RA et al. Matrix metalloprotease 2 (IVIMP-2) and matrix metalloprotease 9 (IVIMP-9) Type IV collagenases in colorectal cancer. Cancer Res. 56,190–196 (1996).
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Stephens RW, Nielsen HJ et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin. Cancer Res. 11,4292-4299 (2000).
   Google Scholar
• Yang JL, Seetoo Dq, Wang Y et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int. J. Cancer 5,431–439 (2000).
   Google Scholar
• •Prognostic role of uPA in colorectal cancer; review of previous analyses.
   Google Scholar
• Abe J, Urano T, Konno H et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor Type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 12, 2602–2611 (1999).
   Google Scholar
• Fujii T, Obara T, Tanno S et al. Urokinase- type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology28, 2299–2308 (1999).
   Google Scholar
• Stephens RVV, Nielsen HJ, Christensen IJ et al Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.' Natl Cancer Inst. 10, 869–874 (1999).
   Google Scholar
• •Prognostic role of uPA in the largest series of patients with colorectal cancer.
   Google Scholar
• Skelly MM, Troy A, Duffy MJ et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin. Cancer Res. 10, 1837–1840 (1997).
   Google Scholar
• Kim SJ, Shiba E, Tsukamoto F et al. The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer. Oncol Rep. 2, 431–435 (1998).
   Google Scholar
• Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. BE j Cancer12, 1793–1801 (1997).
   Google Scholar
• Sato T, Nishimura G, Yonemura Y et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology4, 347–352 (1995).
   Google Scholar
• Mulcahy HE, Duffy MJ, Gibbons D eta]. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet8922, 583–584 (1994).
   Google Scholar
• •Prognostic role of uPA in node-negative colorectal cancer.
   Google Scholar
• Ganesh S, Sier CF, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 15, 4065–4071 (1994).
   Google Scholar
• Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein statement correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55, 1404–1412 (1995).
   Google Scholar
• Johnston PG, Fisher ER, Rockette HE eta]. The role of thymidylate synthase statement in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.' Clin. Oncol 12, 2640–2647 (1994).
   Google Scholar
• •First report on the clinical role of TS in colorectal cancer.
   Google Scholar
• Takenoue T, Nagawa H, Matsuda K et al. Relation between thymidylate synthase statement and survival in colon carcinoma and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann. Surg. Oncol 7, 193–198 (2000).
   Google Scholar
• Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase statement: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6, 1378–1384 (2000).
   PubMedGoogle Scholar
• van Triest B, Pinedo HM, Blaauwgeers JL et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/ platelet-derived endothelial cell growth factor and proliferation markers in colorectal cancer. Clin. Cancer Res. 6, 1063–1072 (2000).
   PubMed Web of Science ®Google Scholar
• Edler D, Kresser U, Ragnhammar P et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin. Cancer Res. 6, 488–489 (2000).
   PubMed Web of Science ®Google Scholar
• Sanguedolce R, Vultaggio G, Sanguedolce F et al. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res. 18, 1515–20 (1998).
   PubMedGoogle Scholar
• Yamachika T, Nakanishi H, Inada K et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 82, 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Cascinu S, Graziano F, Valentini M et al. Vascular endothelial growth factor statement, S-phase fraction and thymidylate quantitation in node-positive colon cancer. Relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann. Oncol (2001) (In Press).
   Google Scholar
• •First report on the clinical role of TS in the adjuvant setting of chemotherapy for colorectal cancer.
   Google Scholar
• Lowe SW Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulatesthe cytotoxicity of anticancer agents. Cell 74, 957–967 (1993).
   PubMedGoogle Scholar
• Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379, 88–91 (1996).
   PubMed Web of Science ®Google Scholar
• Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Natl Cancer Inst. 88, 1442–1455 (1996). Comprhensive review of p53 functions and therapeutic perspectives.
   Google Scholar
• Kressner U, Inganas M, Byding S et al. Prognostic value of p53 genetic changes in colorectal cancer. j Clin. Oncol 17, 593–599 (1999).
   Google Scholar
• Nylander K, Nilsson P, Mehle C, Roos G. p53 mutations, protein statement and cell proliferation in squamous cell carcinomas of the head and neck. BE J. Cancer 71, 826–830 (1995).
   Google Scholar
• Wu X, Boyle JH, Olson DC, Levine AJ. The p53-mdm2 autoregolatory feed-back loop. Genes Dev. 7, 1126–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Borresen-Dale A-L, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res. 4, 203–210 (1998).
   Google Scholar
• Bouzourene H, Gervaz P, Cerottini J-P et al p53 and Ki-ras as prognostic factors for Dukes'stage B colorectal cancer. Eur Cancer 36, 1008–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Elsaleh H, Powell B, Soontrapomchai P et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes'C colon carcinoma. Oncology58, 52–59 (2000).
   PubMed Web of Science ®Google Scholar
• Elsaleh H, Soontrapomchai P, Grieu F, Joseph D, Iacopetta B. p53 alterations have no prognostic or predictive significance in Dukes'C rectal carcinomas. Int. J. Cancer 15, 1239–1243 (1999).
   Google Scholar
• Ahnen DJ, Feigl P, Quan G et al. Ki-ras mutation and p53 overstatement predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study. Cancer Res. 58, 1149–1158 (1998).
   PubMed Web of Science ®Google Scholar
• Pricolo VE, Finkelstein SD, Hansen K et al. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Airh. Sing. 132, 371–375 (1997). p53 mutation by genetic analysis was an independent prognostic factor.
   Google Scholar
• Soong R, Grieu F, Robbins P et al. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer Res. 3, 1405–1411 (1997).
   Google Scholar
• •Largest study on the prognostic role of p53 mutations in colorectal cancer.
   Google Scholar
• Baretton GB, Vogt M, Muller C et al. Prognostic significance of p53 statement, chromosome 17 copy number and DNA ploidy in non-metastasized colorectal carcinoma (stage TB and II). Scancl Castroenterol 31, 481–489 (1996).
   PubMed Web of Science ®Google Scholar
• Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 16, 951–958 (1996).
   Google Scholar
• Bennett MA, Kay EW, Mulcahy H et al ras and p53 in the prediction of survival in Dukes'stage B colorectal carcinoma. j Clin. Pathol 48, M310—M315 (1995).
   Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
   PubMed Web of Science ®Google Scholar
• ••Review on the role of ras oncogene in cancer.
   Google Scholar
• Andreyev HJN, Norman AR, Cunningham D et al Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J. Natl Cancer Inst. 90, 675–684 (1998).
   PubMed Web of Science ®Google Scholar
• ••Collaborative study to determine theimpact of k-ras by collecting data from colorectal cancer patients worldwide.
   Google Scholar
• Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49–58 (1990).
   PubMed Web of Science ®Google Scholar
• Shibata D, Reale MA, Lavin P et al. The DCC protein and prognosis in colorectal cancer. N Engl. J. Merl 335, 1727–1732 (1996).
   PubMed Web of Science ®Google Scholar
• ••Pivotal analysis on the prognostic role ofDCC in colorectal cancer.
   Google Scholar
• O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 70 (Suppl. 6), 1732–1739 (1992).
   Google Scholar
• Jemvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. BE j Cancer 79, 903–908 (1999).
   Google Scholar
• Lanza G, Matteuzzi M, Gafa R et al Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int. J. Cancer79, 390–395 (1998).
   Google Scholar
• Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Castmenterology114, 1188–1195 (1998).
   Google Scholar
• •Analysis addressing patients with node-negative disease.
   Google Scholar
• Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl. J. Merl 331, 213–221 (1994).
   Google Scholar
• Dix BR, Robbins P, Soong R et al. The common moleculagenetic alterations in Dukes'B and C colorectal carcinomas are not short-term prognostic indicators of survival. [nt.j Cancer59, 747–751 (1994).
   PubMed Web of Science ®Google Scholar
• Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal anew mechanism for colonic tumorigenesis. Nature 363, 558–561 (1993).
   Google Scholar
• ••Definition of microsatellite instability andits role.
   Google Scholar
• Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characyeristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am jPathol. 145, 148–156 (1994).
   PubMed Web of Science ®Google Scholar
• Forster S, Sattler HP, Haek M et al. Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein statement of p53 and distinct histomorphologic features. Surgery 123, 13–18 (1998).
   PubMedGoogle Scholar
• Hailing KC, French AJ, McDonnell SK et al Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. Natl Cancer Inst. 91, 1295–1303 (1999).
   Google Scholar
• Gryfe R, Kim H, Hsieh ETK et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl Merl 342, 69–77 (2000).
   PubMed Web of Science ®Google Scholar
• ••Prognostic role of MSI in a population-based series of 587 patients.
   Google Scholar
• Elsaleh H, Joseph D, Grieu F et al. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355, 1745–1750 (2000).
   PubMed Web of Science ®Google Scholar
• Watanabe T, WU TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engif Merl 344, 1196–1206 (2001).
   PubMed Web of Science ®Google Scholar
• ••Latest study of prognostic biomarkers incolorectal cancer.
   Google Scholar
• Mamounas EP Adjuvant chemotherapy for stage II colon cancer: the time has come. Eur. I Surg. Oncol 8, 725–729 (2000).
   Google Scholar
• Wein A, Hahn EG, Merkel S, Hohenberger W Adjuvant chemotherapy for stage II (Dukes' B) colon cancer: too early for routine use. Eur I Sing Oncol 8, 730–732 (2000).
   Google Scholar
• Amadori A, Nanni 0, Marangolo M et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate and fuorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J. Cum Oncol 17, 3125–3134 (2000).
   Google Scholar
• •Benefit of adjuvant chemotherapy in high-risk breast cancer patients.
   Google Scholar
• Chung DC. Molecular prognostic markers and colorectal cancer: the search goes on. Castroenterology114, 1330–1332 (1998).
   PubMedGoogle Scholar
• ••Overview of potential prognostic markersin colorectal cancer.
   Google Scholar
• Offit K. Genetic prognostic markers for colorectal cancer. N Engl. J. Merl 2, 124–125 (2000).
   Google Scholar
• Nicholl ID, Dunlop MG. Molecular markers of prognosis in colorectal cancer. J. Natl Cancer Inst. 15, 1267–1269 (1999).
   Google Scholar
• O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. arca 1, 295–300 (1998).
   Google Scholar
• Piedbois P. Fourth International Conference on Colorectal Cancer: adjuvant treatment of colon cancer. Semin. Oncol (Suppl. 1), 1–3 (2001).
   Google Scholar